Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + lenvatinib + TACE
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Intra-arterial
01
Overview
toripalimab + lenvatinib + TACE is a combination therapy regimen primarily investigated as a conversion therapy for patients with initially unresectable or potentially resectable hepatocellular carcinoma (HCC). The regimen consists of **toripalimab**, a humanized IgG4 monoclonal antibody developed by Junshi Bioscience that targets the programmed cell death protein 1 (PD-1) receptor to restore anti-tumor immune responses; **lenvatinib**, a multi-targeted tyrosine kinase inhibitor developed by Eisai that inhibits vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET; and **transarterial chemoembolization (TACE)**, a locoregional procedure that delivers concentrated chemotherapy directly to the tumor while inducing ischemia through embolization of the tumor-feeding arteries. This triple combination aims to achieve high objective response rates (ORR) and facilitate surgical resection in patients with advanced or intermediate-stage HCC.
- Brand names
- Tuoyi
- Other names
- toripalimab + lenvatinib + TACEToripalimab plus Lenvatinib and TACEJS001 + lenvatinib + TACE
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on toripalimab + lenvatinib + TACE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + lenvatinib + TACE.